CVS Health Stock News

CVS Health is successfully navigating industrywide and company-specific headwinds while maintaining a solid dividend program. Johnson & Johnson's rock-solid balance sheet and ability to develop brand-new products make its 62-year dividend growth streak safe.

These three stocks all looked down and out toward the end of 2024. Through the first 10 months of 2025, however, they were all up more than 70%.

Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tuesday, citing people familiar with the matter.

Current CVS Health CEO David Joyner took over a little over a year ago. The company's growth rate has been improving and its overall financial results have been stronger.

WOONSOCKET, R.I. , Nov. 10, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold its Investor Day on December 9 th, 2025.

Skyrizi and Rinvoq sales are pushing AbbVie's sales higher. UnitedHealth Group raised its full-year guidance and is rebounding from a disastrous 2025.

CVS Health has improved its financial results this year. The company's efforts could allow it to maintain that momentum.

FT. LAUDERDALE, Fla.--(BUSINESS WIRE)-- #TRUEMETRIX--Trividia Health, Inc., announced today that it's TRUE METRIX® Self-Monitoring Blood Glucose Systems are now preferred for commercial patients on CVS Caremark Commercial Template Formularies in the United States, replacing OneTouch® branded blood glucose monitors and test strips. The TRUE METRIX® portfolio delivers scientifically backed perfor...